MedTrace Logo

Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer

NCT01342354 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-07-18

Study results available
· View outcomes & findings →

Summary

This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.

Conditions

Interventions

RADIATION

Stereotactic Radiation 10 Gy

10 Gy three times over 10 days

RADIATION

Stereotactic Radiation 12.5 Gy

12.5 Gy three times over 10 days

RADIATION

Stereotactic Radiation 15 Gy

15 Gy three times over 10 days

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Stanley Liauw, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-14
Primary Completion
2020-08-31
Completion
2022-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342354 on ClinicalTrials.gov